Blocking type PD-L1 single-domain camel antibody and application thereof
US11912770B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2019 |
| Grant date | Feb 27, 2024 |
| Priority date | — |
| Expiry date | Dec 23, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are a single-domain antibody against human programmed death-ligand 1 (PD-L1) and application thereof. The PD-L1 binding molecule of the present invention can be used for treating and/or preventing, or diagnosing PD-L1 related diseases such as tumors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.